• Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones 

      Clarelli, Fabrizio; Palmer, Adam; Singh, Bhupender; Storflor, Merete; Lauksund, Silje; Cohen, Ted; Abel, Sören; Abel zur Wiesch, Pia (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-08-14)
      Antibiotic resistance is rising and we urgently need to gain a better quantitative understanding of how antibiotics act, which in turn would also speed up the development of new antibiotics. Here, we describe a computational model (COMBAT-COmputational Model of Bacterial Antibiotic Target-binding) that can quantitatively predict antibiotic dose-response relationships. Our goal is dual: We address a ...
    • RESTAMP – Rate estimates by sequence-tag analysis of microbial populations 

      Mahmutovic, Anel; Gillman, Aaron Nicholas; Lauksund, Silje; Robson Moe, Natasha-Anne; Manzi, Aimé; Storflor, Merete; Abel-Zur Wiesch Genannt Hülsho, Pia Karoline; Abel, Sören (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-01-19)
      Microbial division rates determine the speed of mutation accumulation and thus the emergence of antimicrobial resistance. Microbial death rates are affected by antibiotic action and the immune system. Therefore, measuring these rates has advanced our understanding of host-pathogen interactions and antibiotic action. Several methods based on marker-loss or few inheritable neutral markers exist that ...
    • ZN148 Is a Modular Synthetic Metallo-beta-Lactamase Inhibitor That Reverses Carbapenem Resistance in Gram-Negative Pathogens In Vivo 

      Samuelsen, Ørjan; Åstrand, Ove Alexander Høgmoen; Frøhlich, Christopher; Heikal, Adam; Skagseth, Susann; Carlsen, Trine Josefine Olsen; Leiros, Hanna-Kirsti S.; Bayer, Annette; Schnaars, Christian; Kildahl-andersen, Geir; Lauksund, Silje; Finke, Sarah; Huber, Sandra; Gjøen, Tor; Andresen, Adriana Magalhaes Santos; Økstad, Ole Andreas; Rongved, Pål (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-05-21)
      Carbapenem-resistant Gram-negative pathogens are a critical public health threat and there is an urgent need for new treatments. Carbapenemases (β-lactamases able to inactivate carbapenems) have been identified in both serine β-lactamase (SBL) and metallo-β-lactamase (MBL) families. The recent introduction of SBL carbapenemase inhibitors has provided alternative therapeutic options. Unfortunately, ...